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RAC1b is a hyperactive variant of the small GTPase RAC1 known to be a relevant molecular player in different cancers. Previous
studies from our group lead to the evidence that its overexpression in papillary thyroid carcinoma (PTC) is associated with
an unfavorable prognosis. In the present study, we intended to extend the analysis of RAC1b expression to thyroid follicular
neoplasms and to seek for clinical correlations. RAC1b expression levels were determined by RT-qPCR in thyroid follicular tumor
samples comprising 23 follicular thyroid carcinomas (FTCs) and 33 follicular thyroid adenomas (FTAs). RAC1b was found to
be overexpressed in 33% of carcinomas while no RAC1b overexpression was documented among follicular adenomas. Patients
with a diagnosis of FTC were divided into two groups based on longitudinal evolution and final outcome. RAC1b overexpression
was significantly associated with both the presence of distant metastases (𝑃 = 0.01) and poorer clinical outcome (𝑃 = 0.01)
suggesting that, similarly to that previously found in PTCs, RAC1b overexpression in FTCs is also associated with worse outcomes.
Furthermore, the absence of RAC1b overexpression in follicular adenomas hints its potential as a molecular marker likely to
contribute, in conjunction with other putative markers, to the preoperative differential diagnosis of thyroid follicular lesions.
1. Introduction
More than 95% of thyroid cancers originate from thyroid fol-
licular epithelial cells. Among the well-differentiated forms,
papillary thyroid carcinoma (PTC) is the most prevalent one,
accounting for 75–80% of cases, followed by the follicular
thyroid carcinoma (FTC), which represents approximately
10–15% of all thyroid cancers [1]. Distinction between FTC
and its benign counterpart (follicular adenoma) is impossible
on cytological grounds. Pathological examination show-
ing capsular or vascular invasion is necessary to establish
the diagnosis of FTC [2–4]. Activating alterations in the
canonical Ras/Raf/MEK/ERK pathway (MAPK pathway) are
considered to have key role in thyroid carcinogenesis [1, 5].
The BRAF V600E activating mutation is the most frequent
genetic alteration in PTCs. In FTCs, however, this alteration
is virtually absent and oncogenic alterations of RAS proteins
are instead the most prevalent ones [1, 5]. Although a single
oncogenic alteration in MAPK pathway might be sufficient
to drive thyroid cell neoplastic transformation, further sup-
portive molecular events are likely to be associated with
thyroid malignant progression leading to more aggressive
phenotypes and poorer clinical outcomes. We have recently
described RAC1b, a splicing variant of RAC1, as a potential
new prognostic marker for clinical outcome in PTC patients
[6].
RAC1 belongs to the Rho family of Ras-like small GTP-
binding proteins, a class of molecular “switches” that regulate
cellular functions by cycling between an inactive, GDP-
and an active, GTP-bound state [7]. These small GTPases
have been implicated in cancer since they regulate signaling
pathways involved in processes such as gene expression,
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cell proliferation, and cell migration [8]. The RAC1 splice
variant, RAC1b, contains 57 additional nucleotides that result
in an in-frame insertion of 19 amino acid residues in the
vicinity of an important regulatory region of the GTPase
[9]. This confers RAC1b activating properties and a selective
downstream signaling in comparison to RAC1 [10].
RAC1b overexpression has been documented in col-
orectal, breast, lung, and pancreatic cancer [9, 11–15]. In
our previous study, we reported for the first time RAC1b
expression in thyroid tissue [6]. We have, previously, shown
that RAC1b is overexpressed in PTCs compared to normal
thyroid tissue and that RAC1b overexpression is significantly
associated with BRAF V600E mutation and poorer clinical
outcome in PTC [6]. Here, we aimed to broaden the study
of RAC1b expression to follicular lesions including follicular
adenomas and follicular carcinomas and to seek for clinical
correlations.
2. Materials and Methods
2.1. Tumor Samples. Samples representative of 23 FTCs and
samples representative of 33 follicular adenomas from 56
patients, who underwent surgery at our institution, were
analyzed. Samples were collected at surgery and immediately
frozen and stored in liquid nitrogen. Tissue sample collection
was carried out in accordance with protocols approved by the
institutional review board and written informed consent was
obtained together with the consent for surgery.
2.2. RNA Extraction, cDNA Synthesis, andMutational Screen-
ing of KRAS, HRAS, and NRAS. Total RNA was obtained
from frozen tissues using RNA easykit (Qiagen), according to
manufacturer’s instructions, and 2 𝜇g was reverse transcribed
using random primers and SuperScript II (Invitrogen).
Mutational analysis of KRAS, HRAS, and NRAS was per-
formed by Sanger sequencingmethod: the full coding regions
of RAS transcripts were amplified by reverse transcription
polymerase chain reaction (RT-PCR) (primers and PCR
conditions available upon request). PCR purified products
were directly sequenced using BigDyeTerminator v1.1 Cycle
Sequencing Kit (Applied Biosystems, Foster City, CA, USA).
Sequencing products were analyzed using ABI PRISM 3130
Genetic Analyzer (Applied Biosystems).
2.3. RT-qPCR. The RAC1b and total RAC1 expression levels
were quantified by quantitative reverse transcription poly-
merase chain reaction (RT-qPCR) on an ABI Prism 7900HT
Sequence Detection System, as previously described [6]. For
each sample, RAC1b levels were normalized to total RAC1
(RAC1b + RAC1) expression level. RAC1b normalized values
were then expressed relative to that of a pool of normal
thyroid tissues, used as reference sample. Expression values
correspond to arbitrary units representing fold differences
relative to the reference sample. RAC1b overexpression was
defined as a value above a threshold level of RAC1b expression
corresponding to the mean plus two standard deviations
of the RAC1b expression level found in the set of normal
thyroid tissue samples; this threshold level was set at 2.133
(arbitrary units). Similarly, to monitor total RAC1 expression
among samples, total Rac1 levels were normalized to beta-
actin expression level (housekeeping gene normalization)
and expressed relative to that of the reference sample.
2.4. Protein Lysates andWesternBlotting. Total protein lysates
were prepared from frozen thyroid tissues as previously
described [6]. The primary antibodies rabbit polyclonal
anti-Rac1b (Millipore) and mouse monoclonal anti-𝛽-actin
(Sigma) were used in Western blot at 1 : 1000 and 1 : 3000
dilutions, respectively. Detection was carried out using sec-
ondary peroxidase-conjugated anti-mouse IgG (Bio-Rad) or
anti-rabbit IgG (Bio-Rad) antibodies followed by chemilumi-
nescence.
2.5. Statistical Analysis. Statistical analysis was carried out
using GraphPad Prism statistical software (San Diego, CA).
When appropriate, values are expressed as mean ± SD.
Statistical comparisons of rates and proportions were made
using unpaired two-tailed Student’s 𝑡-test or the two-tailed
Fisher exact test, when appropriated. Statistical significance
was accepted at 𝑃 < 0.05.
3. Results
3.1. RAC1b Is Overexpressed in FTC. Total RAC1 and RAC1b
expression levels were assessed by RT-qPCR. No significant
differences in total RAC1 levels were found between FTCs
and FTAs samples. RAC1b expression levels in tumor samples
were obtained following normalization to the levels from a
pool of normal thyroid tissues used as reference sample in
all RT-qPCR assays. The mean level for RAC1b expression
was significantly higher in FTCs (2.137 ± 0.5515) compared
to FTAs (0.9656 ± 0.07342) (𝑃 value = 0.0152, two-tailed
Student’s 𝑡-test), corresponding to a 2.2 mean fold increase
in the levels of RAC1b expression (Figure 1(a)).
In order to distinguish tumors that overexpressed RAC1b
from those that did not, we defined a threshold level of
RAC1b expression relative to the normal thyroid tissue
(see Section 2) above where we considered RAC1b to be
overexpressed. RAC1b was found to be overexpressed in 7 out
of 23 FTCs (30%). Notably, none of the cases belonging to the
FTAs group was found to overexpress RAC1b. Consistently,
the difference in RAC1b overexpression between follicular
adenomas and carcinomas was statistically significant (𝑃
value = 0.001, two-tailed Fisher’s exact test; Figure 1(b)).
Since the assessment of RAC1b overexpression by
immunohistochemistry in paraffin-embedded tissues might
be relevant for diagnostic purposes, we further explored
this possibility using the only RAC1b specific antibody that
is commercially available. Unfortunately, we were not able
to detect a clear difference in RAC1b protein levels either
comparing RAC1b overexpressing and nonoverexpressing
tumors or tumor and normal tissue. Nevertheless, a notorious
difference in RAC1b expression was observed when protein
levels were assessed by Western blot. This discrepancy is
likely to be due to antibody nonspecific binding as pointed
out by the band of ≅50 kDa observed in the immunoblot
























10 20 300 5040
n#
















5 10 15 200
n#







5 10 15 200
n#
RAC1b overexpression: distant metastasis
(e)
Figure 1: RAC1b expression in follicular thyroid tumors. (a) Expression levels of RAC1b among FTCs (𝑛 = 23) and FTAs (𝑛 = 33). RAC1b
expression levels, quantified by qRT-PCR, correspond to arbitrary units representing fold differences relative to the reference sample; the
threshold value defining RAC1b overexpressionwas set at 2.133 (corresponding to themean plus two standard deviations of RAC1b expression
level in a set of normal thyroid tissue samples). (b) Comparative analysis of RAC1b overexpression (RAC1b+) between follicular thyroid
carcinomas (FTC) and follicular thyroid adenomas (FTA). (c)Western blot analysis of RAC1b protein levels in normal thyroid (N) and RAC1b
overexpressing (T+) and nonoverexpressing (T−) tumors; protein molecular weight marker (M). (d) Association of RAC1b overexpression
(RAC1b+) with clinical outcome (Group I: NED: no evidence of disease, BED: biochemical evidence of disease; Group II: SED: structural
evidence of disease, D: death due to disease). (e) Association of RAC1b overexpression (RAC1b+) with the presence (M1) or absence (M0) of
distant metastases.
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(Figure 1(c)) that hampers an accurate analysis by immuno-
histochemistry.
3.2. RAC1b Overexpression Is Associated with Presence of
Distant Metastases and Poorer Clinical Outcomes. To inves-
tigate whether RAC1b overexpression was associated with
histopathological parameters and clinical outcome, FTCs
were grouped based on the clinical data available (see Table 1).
A comparative analysis between FTC patients without
distant metastases (M0, 16 cases) versus FTC patients with
distant metastases (M1, 7 cases) disclosed a higher prevalence
of RAC1b overexpression in the latter group (M1—5/7; M0—
2/16). The association between RAC1b overexpression and
presence of distant metastases was statistically significant (𝑃
value = 0.01; Figure 1(c)). No statistical significant correlation
was found between RAC1b overexpression and histopatho-
logical features such as multifocality, angioinvasion, Hürthle
cell subtype, or presence of poorly differentiated areas.
FTCs were grouped based on the final clinical outcome.
Group I (70% of patients) included patients who reached full
sustained remission (no evidence of disease) and patients
presenting only biochemical evidence of disease. In contrast,
Group II (30% of patients) included patients with structural
evidence of disease and those who died due to disease
progression. The correlation between RAC1b overexpression
and Group II was statistically significant (𝑃 value = 0.01;
Figure 1(d)), reinforcing that RAC1bmight be associated with
poorer clinical outcomes in FTC patients.
4. Discussion
At present, stratification risk of patients with follicular cell-
derived thyroid carcinomas mainly relies on clinical and
histological criteria proved to be insufficient to tailor case
management to individual risk levels [16]. A major effort
to improve the panel of prognostic indicators has entailed
the molecular characterization of thyroid tumors, seeking for
molecular markers with a reliable prognostic value [17, 18].
Previous studies from our group provided evidence for a
contributory role of RAC1b in PTC development and clinical
outcome [6]. We, therefore, hypothesized that RAC1b might
also be involved in follicular thyroid carcinoma development.
Moreover, taking into account the impossibility of distin-
guishing a follicular carcinoma from a follicular adenoma,
preoperatively, we wondered whether the RAC1b expression
could contribute to the distinction of these two entities.
Our data suggest that RAC1b is likely to have a differential
expression in follicular adenomas and carcinomas, since
RAC1b was overexpressed in 30% of FTCs whereas no
overexpression was found among FTAs. Furthermore, we
also found a significant correlation between RAC1b overex-
pression and the presence of distant metastases, hence, with
poorer outcome.
Papillary thyroid carcinoma and follicular thyroid carci-
noma are collectively designated well-differentiated thyroid
carcinomas (DTCs). Nonetheless, the underlying genetic
alterations promoting the development of these two types
of thyroid cancer are different. The BRAF V600E mutation
occurs in approximately 45% of PTCs. It is not definitely
established whether BRAF V600E initiates PTC tumorige-
nesis or is a secondary event. In a previous study, we have
shown that RAC1b overexpression significantly associates
with BRAF V600E mutation in PTCs [10]. This suggests
that a functional cooperation between RAC1b and BRAF
V600E may play a role in PTC progression, similarly to
that previously described in colorectal cancer [11]. In fact,
in colorectal tumors, the elevated levels of Rac1b expression
were significantly associated with mutant BRAF but not with
mutant K-RAS genotype, suggesting that RAC1b is needed
to sustain BRAF-induced but not RAS-induced cell transfor-
mation.Themechanism of action of RAC1b in tumorigenesis
may, however, differ in other tissues.
Concerning follicular thyroid lesions, BRAF V600E is
virtually absent in this tumor subtype and the most common
MAPK-pathway alteration is the presence of RAS mutations.
Notably and contrary to that found in colorectal cancer,
oncogenic alterations in K-RAS have also been associated
with RAC1b overexpression in lung cancer and RAC1b was
shown to promote K-RAS-induced lung tumorigenesis [13].
In our series of FTC patients no association between RAC1b
overexpression and RAS mutations could be observed. How-
ever, this might be due to the small sample size. Despite
these, the incidence of RASmutations in follicular adenomas,
which are considered premalignant lesions, suggests a role
for RAS in early phases of follicular cell tumorigenesis. This
is in agreement with the hypothesis that the progression
of a premalignant lesion into cancer, with different grades
of aggressiveness, is linked to a continuum of molecular
changes dependent on late and/ormodifier events that are not
necessarily exclusive of a specific type of tumor ormechanism
of tumorigenesis. Overexpression of RAC1b may thus be one
of these modifier events that can occur in different subtypes
of DTCs despite having different triggers.
5. Conclusion
The clinical usefulness of RAC1b overexpression in the
context of thyroid malignancies remains to be definitively
established. Nevertheless, our data suggest that RAC1b might
be involved in the modulation of malignant progression of
FTCs, contributing to poorer clinical outcomes, similarly to
that previously documented in PTCs. Our data also support
the potential of RAC1b as a molecular marker likely to
contribute, in conjunctionwith other putativemarkers, to the
diagnosis and prognosis of FTCs.
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